Research Topics
Species | Del D MillerSummaryAffiliation: University of Iowa Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysisDel D Miller
Department of Psychiatry, University of Iowa, Carver College of Medicine, Iowa City, IA 52242 1000, USA
J Clin Psychiatry 68:1901-6. 2007..To comparatively assess the incidence of tardive dyskinesia in patients with schizophrenia receiving either aripiprazole or haloperidol...
Extrapyramidal side-effects of antipsychotics in a randomised trialDel D Miller
University of Iowa Carver College of Medicine, Iowa City, IA 52242 1000, USA
Br J Psychiatry 193:279-88. 2008..There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs...- Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphismDel D Miller
Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242 1000, USA
Am J Med Genet B Neuropsychiatr Genet 133:97-100. 2005..Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele... - Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller
University of Iowa Carver College of Medicine, Psychiatry Research, 2 105 MEB, 500 Newton Rd, Iowa City, IA 52242 1000, USA
Schizophr Res 80:33-43. 2005..To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment... - The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
J Clin Psychiatry 68:1751-62. 2007.... 
Treatment outcomes of patients with tardive dyskinesia and chronic schizophreniaStanley N Caroff
Department of Psychiatry, Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, USA
J Clin Psychiatry 72:295-303. 2011..We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD...- Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disordersMaithri Prabhakar
Department of Psychiatry, Carver College of Medicine, College of Public Health, University of Iowa, Iowa City, USA
Pharmacotherapy 31:806-12. 2011..To identify the factors associated with newly prescribed, first-line, second-generation antipsychotics (SgAs) associated with weight gain-olanzapine, risperidone, and quetiapine... - Substance use and schizophrenia: adverse correlates in the CATIE study sampleKarin E Kerfoot
Department of Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
Schizophr Res 132:177-82. 2011.... - Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trialMiranda H Chakos
Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn, 11572, USA
Psychiatr Serv 57:1094-101. 2006..CONCLUSIONS: Concomitant use of psychotropic medications to treat people with schizophrenia is common. Empirical data demonstrating the effectiveness of many of these agents for this population are lacking... - The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
J Clin Psychiatry 65:500-8. 2004..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators... - Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescentsChadi Albert Calarge
Department of Psychiatry, The University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA
J Child Adolesc Psychopharmacol 21:163-9. 2011..Little is known about risperidone metabolism in a clinical sample, where polypharmacy is common. Such knowledge is important since several of its side effects are dose dependent... - Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescentsChadi A Calarge
The University of Iowa Carver College of Medicine, Iowa, USA
Pharmacogenet Genomics 19:373-82. 2009..To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone... - Evidence for accelerated vascular aging in bipolar disorderSimrit K Sodhi
Department of Psychiatry, Roy J and Lucille A Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242 1057, United States
J Psychosom Res 73:175-9. 2012..We measured vascular stiffness in a cross-sectional sample of participants with bipolar disorder and compared results to published normative data to assess time-course and relationship to behavioral risk factors... - Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorderJess G Fiedorowicz
Department of Psychiatry, Roy J and Lucille A Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA
Ann Clin Psychiatry 20:131-7. 2008..We hypothesized outpatients with bipolar disorder would exhibit excess cardiovascular risk factors, particularly among prevalent users of the second-generation antipsychotics associated with weight gain and valproic acid derivatives... - The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated statesPatricia Westmoreland Corson
Mental Health Clinical Research Center, Department of Psychiatry, The University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
Biol Psychiatry 52:855-62. 2002.... - Clozapine and tardive dyskinesiaDel D Miller
Am J Psychiatry 160:588. 2003 - Clinicians' recognition of the metabolic adverse effects of antipsychotic medicationsPeter F Buckley
Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912 3800, USA
Schizophr Res 79:281-8. 2005..The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice... - Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE studyMarvin S Swartz
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
J Nerv Ment Dis 194:164-72. 2006.... - Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variantsVicki L Ellingrod
University of Michigan College of Pharmacy, Department of Clinical Sciences, School of Medicine, Ann Arbor 48109, USA
Schizophr Res 98:47-54. 2008.... - The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophreniaYing Chi Lin
Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, 48109, USA
Ther Drug Monit 28:668-72. 2006..The PGP C3435T genotype may help to determine positive symptom reduction from olanzapine clinically, but these findings should be replicated in a larger sample of subjects... - Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophreniaVicki L Ellingrod
Department of Psychiatry in the University of Michigan College of Pharmacy and College of Medicine, Ann Arbor, Michigan 48109, USA
Psychopharmacol Bull 40:57-62. 2007..The objective of the current investigation was to determine the relationship between polymorphisms of the leptin system (leptin gene and leptin receptor) and olanzapine-induced weight gain in persons with schizophrenia... - Sex, race, and smoking impact olanzapine exposureKristin L Bigos
Department of Pharmaceutical Sciences, University of Pittsburgh, School of Pharmacy, 805 Salk Hall, 3501 Terrace St, Pittsburgh, PA 15261, USA
J Clin Pharmacol 48:157-65. 2008..0001). Differences in olanzapine exposure due to sex, race, and smoking may account for some of the variability in response to olanzapine... - The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE studyMarvin S Swartz
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC 27710, United States
Schizophr Res 100:39-52. 2008..This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances... - Pharmacogenetics and schizophreniaAdriana Foster
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
Psychiatr Clin North Am 30:417-35. 2007.... - Baseline neurocognitive deficits in the CATIE schizophrenia trialRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
Neuropsychopharmacology 31:2033-46. 2006..Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity... - Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE studyMarvin S Swartz
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
Psychiatr Serv 57:1110-6. 2006..This study examined the relationship between substance use and psychosocial functioning in schizophrenia...
Research Grants
- ANTIPSYCHOTIC TREATMENT RESPONSEDel Miller; Fiscal Year: 2004..This award will also serve as a mechanism by which the candidate can establish professional collaborative relationships with his mentors and provide him with the background for ongoing research leading to an independent research career. ..
- Relapse Prevention: Long-Acting Atypical AntipsychoticsDel Miller; Fiscal Year: 2007..Even relatively modest delays in relapse and improvement of long term functioning potentially resulting from a long acting second-generation medication can translate into substantial public health benefits. ..